Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant + apatinib for HR-positive, HER2-negative advanced breast cancer
ChiCTR1900021617Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fulvestrant and Rivoceranib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: clinical benefit rate. Started Jan 2019; status: recruiting.
02
Drugs
fulvestrantRivoceranib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900021617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021617.